Bioasis Technologies Inc.
BTI
Clasificación en acciones
#39866
Bioasis Technologies Inc. is a development-stage biopharmaceutical firm focused... Bioasis Technologies Inc. is a development-stage biopharmaceutical firm focused on innovating diagnostic methods and therapeutic solutions for a range of neurological conditions. The company's primary technological asset is the xB3 platform, engineered to enable the transport of medicinal compounds across the often-impenetrable blood-brain barrier. This capability is crucial for addressing central nervous system disorders, including various brain cancers, metabolic dysfunctions, and neurodegenerative illnesses. Bioasis is actively advancing its in-house pipeline with programs such as xB3-001 for brain metastases, xB3-002 for glioblastoma, and xB3-007 for neurodegenerative diseases, all designed to offer both symptomatic relief and disease-modifying benefits. The company has also established numerous strategic alliances. These include a partnership with Aposense Limited to deliver siRNA therapeutics for CNS disorders; a collaboration with Oxyrane UK Ltd. to combine the xB3 technology with Oxyrane's OxyCAT platform for enhanced enzyme replacement therapy targeting the brain; an agreement with Janssen Biotech, Inc. for the discovery, development, and commercialization of novel products leveraging the xB3 platform; and a research and licensing deal with Neuramedy Co Ltd. to develop and market an xB3-enhanced version of their antibody, Tomaralimab. Founded in 2006, Bioasis Technologies Inc. is headquartered in New Haven, Connecticut.
Precio por acción
$0.00366968
Última sincronización: 2024-07-23
Capitalización bursátil
$291.42K
Cambio (1 día)
-0.81%
Cambio (1 año)
1,734.84%
País
US
Comercio Bioasis Technologies Inc. (BTI)
Categoría
Healthcare
Historial de desdoblamientos de acciones de Bioasis Technologies Inc. (BTI)
La acción Bioasis Technologies Inc. (símbolo: BTI) tuvo un total de 0 desdoblamientos.
El desdoblamiento más reciente ocurrió el Oct 20, 2026.
Una acción BTI comprada antes de Oct 20, 2026 equivaldría hoy a 0 acciones BTI.
El desdoblamiento más reciente ocurrió el Oct 20, 2026.
Una acción BTI comprada antes de Oct 20, 2026 equivaldría hoy a 0 acciones BTI.
Lista de desdoblamientos de acciones
| Año | Desdoblamiento | Multiplicador | Multiplicador acumulado |
|---|---|---|---|
| Not enough data for the provided dates. | |||
Desdoblamientos de acciones de empresas similares o competidoras
| Empresa | Número de desdoblamientos de acciones | Multiplicador acumulado | País |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
